By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – A Nasdaq panel has granted Pressure BioSciences' request for continued listing on the exchange, the company said today.
Separately, Nasdaq said that Rosetta must regain compliance with the minimum $1.00 bid price requirement for continued listing on Nasdaq by Aug. 8, 2011, for a minimum of 10 consecutive business days.
CombiMatrix had voluntarily applied for the transfer rather than submit a plan to the exchange to regain compliance with Nasdaq Global Market listing requirements.